Golimumab for Adherence in Rheumatoid Arthritis
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: Golimumab
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT03729349
- Locations
- 🇨🇦
Dr. Abraham Chaiton Medicine Professional Corporation, Toronto, Ontario, Canada
🇨🇦Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
🇨🇦K-W Musculoskeletal Research Inc, Kitchener, Ontario, Canada
A Study of Participants With Advanced Prostate Cancer in Canada
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Other: Standard of Care
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT03501173
- Locations
- 🇨🇦
Scarborough Health Network, Toronto, Ontario, Canada
🇨🇦CHU de Québec Université Laval, Quebec, Canada
🇨🇦Prostate Cancer Centre, Calgary, Alberta, Canada
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 538
- Registration Number
- NCT02688075
Observational Study of Golimumab Intravenous Infusion
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Golimumab Intravenous
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT02390700
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT02364531
An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Drug: Other antiretroviral medications
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01615601
An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Other: No intervention
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT01613404
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: CNTO 1959 (100 mg)Drug: CNTO 1959 (5 mg)Drug: CNTO 1959 (15 mg)Drug: CNTO 1959 (50 mg)Drug: CNTO 1959 (200 mg)Drug: Placebo
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 293
- Registration Number
- NCT01483599
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
Phase 4
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Infliximab 5 mg/kg body weight infused over 2 hours
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT01181765
Biologic Treatment Registry Across Canada
Completed
- Conditions
- Arthritis, PsoriaticSpondyloarthritis, AxialArthritis, Rheumatoid
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Inc.
- Target Recruit Count
- 2821
- Registration Number
- NCT00741793
© Copyright 2025. All Rights Reserved by MedPath